Greenwich LifeSciences Reaches Milestone in FLAMINGO-01 Trial, Screens Over 1,000 Patients

Greenwich LifeSciences has screened over 1,000 patients in its FLAMINGO-01 trial, evaluating GLSI-100 for breast cancer recurrence prevention. The trial has active sites in 40 US and 100 EU locations, with a strategy to continue enrolling patients in both HLA-A*02 and non-HLA-A*02 arms until interim analyses are conducted. The high screening rate may allow for higher enrollment rates and event rates, as well as the potential to maximize indications across multiple HLA types in larger patient populations.